Activating mutations of epidermal growth factor receptor (EGFR), including a deletion in exon 19 and an L858R mutation in exon 21, are a driving force for some non-small cell lung cancer (NSCLC)1–3. Here, EGFR is linked to non-small cell lung carcinoma.